Published 8 days ago • loading... • Updated 8 days ago

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Oncolytics Biotech received a notification letter from Nasdaq on February 13, 2025, stating it is not in compliance with the minimum bid price requirement as its share price was below $1.00 for 30 consecutive business days.
The company has until August 12, 2025, to regain compliance with the minimum bid price requirement, according to the notice they received.
Despite this notification, the company's ordinary shares will continue to trade uninterrupted on Nasdaq under the ticker 'ONCY.'
Oncolytics is advancing clinical trials for pelareorep in metastatic breast cancer and pancreatic cancer, which have received Fast Track designation from the FDA.

Insights by Ground AI

Does this summary seem wrong?

33 Articles

All

Left

Center

Right

hartfordcitynewstimes.com

+31 Reposted by 31 other sources

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

SAN DIEGO and CALGARY, AB, Feb. 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it received a delinquency notification letter (the "Notice") from the Listing…

8 days ago·Hartford City, United States

Read Full Article

stocktitan.net

Nasdaq Issues Warning: Oncolytics Biotech Faces Critical 6-Month Deadline to Avoid Delisting

Oncolytics receives Nasdaq notification for trading below $1.00, granted 180-day grace period until August 2025 to regain compliance and maintain listing.

8 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year